Respiratory Tract Infections

Respiratory Syncytial Virus (RSV) is a common respiratory tract infection, especially affecting infants and young children. RSV is a leading cause of bronchiolitis and pneumonia in this age group. The virus causes symptoms such as cough, wheezing, nasal congestion, and difficulty breathing. While RSV infections are generally mild in healthy individuals, they can lead to severe respiratory complications in vulnerable populations, including premature infants and elderly adults. RSV transmission occurs through respiratory droplets, and the virus can remain viable on surfaces for an extended period. Prevention strategies involve practicing good hand hygiene, avoiding close contact with sick individuals, and implementing infection control measures in healthcare settings. Although no specific antiviral treatment is universally recommended, certain populations at high risk may receive immunoprophylaxis with palivizumab to reduce the severity of RSV infections. Research in RSV focuses on understanding the immune response to the virus, developing antiviral therapies, and designing effective vaccines. The development of an RSV vaccine remains a priority, especially given the impact of RSV on pediatric health. Public health efforts aim to mitigate the burden of RSV infections through vaccination campaigns and targeted interventions to protect vulnerable populations.